FDA Brief

Warning letters Drugs

FDA warning letter to

Ayuryoga, Inc.

High riskIssued May 19, 2022Posted May 24, 2022Center for Drug Evaluation and Research | CDER

FDA warned Ayuryoga/Kottakkal Ayurveda USA that its ayurvedic products are unapproved new drugs promoted with disease-treatment claims online.

What happened

In March 2022, FDA reviewed the company’s website and its Facebook, Instagram, LinkedIn, and Twitter pages, which direct consumers to the website to buy products. FDA found product pages and posts claiming the ayurvedic products treat or relieve diseases such as diabetes, high blood pressure, arthritis, asthma, and others. FDA says these claims make the products drugs, and they are unapproved new drugs sold without FDA approval.

What FDA found

  1. The website and social media claims make the ayurvedic products drugs because they are intended to treat, cure, mitigate, or prevent disease or affect body structure or function.

    FD&C Act § 201(g)(1), 21 U.S.C. § 321(g)(1)
  2. The products are new drugs because FDA does not generally recognize them as safe and effective for their labeled uses.

    FD&C Act § 201(p), 21 U.S.C. § 321(p)
  3. The company introduced or delivered the products into interstate commerce without FDA approval.

    FD&C Act §§ 505(a), 301(d), 21 U.S.C. §§ 355(a), 331(d)
  4. FDA says drug claims appear for a wide range of products, not only the examples named in the letter.

    FD&C Act §§ 505(a), 301(d), 21 U.S.C. §§ 355(a), 331(d)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of steps taken to address violations and prevent recurrence, with related documentation, referencing CMS 628168. If corrective actions cannot be completed in that time, the company must state why and when it will finish.

Who should pay attention

  • retailers and distributors selling ayurvedic products
  • ayurvedic and supplement brands making disease claims online
  • quality and regulatory teams reviewing website and social media labeling

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk